Modern Healthcare2d
FDA warns Dexcom over continuous glucose monitor testing
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
Dexcom’s FDA warning letter reveals unauthorized changes to sensors
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
Zacks.com on MSN1d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...
Medscape4d
Dexcom’s 15-day CGM Adds Wear Time, Accuracy to Current G7
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
15.5-day G7 integrated continuous glucose monitor in adults with diabetes shows positive results
In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...
Medical Xpress4d
15.5-day G7 integrated continuous glucose monitor in adults with diabetes shows positive results
The 15.5-day Dexcom G7 continuous glucose monitor (CGM) demonstrated high accuracy and safety in adults with diabetes, meeting and exceeding integrated CGM performance goals.
Nasdaq2d
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.
Blood Glucose Wearables May Have A Bright Future, Study Says
A study that looks into the potential of wearables to non-invasively measure blood glucose has come up with promising results ...